Joshua Rhett to Antineoplastic Agents
This is a "connection" page, showing publications Joshua Rhett has written about Antineoplastic Agents.
Connection Strength
0.434
-
Biology, pathology, and therapeutic targeting of RAS. Adv Cancer Res. 2020; 148:69-146.
Score: 0.416
-
Targeting connexin 43 with a-connexin carboxyl-terminal (ACT1) peptide enhances the activity of the targeted inhibitors, tamoxifen and lapatinib, in breast cancer: clinical implication for ACT1. BMC Cancer. 2015 Apr 03; 15:296.
Score: 0.018